333 related articles for article (PubMed ID: 27836248)
21. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
22. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells.
Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Martin-Castillo B; Menendez JA
Curr Mol Med; 2010 Oct; 10(7):674-91. PubMed ID: 20712585
[TBL] [Abstract][Full Text] [Related]
23. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
24. Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.
Crawley D; Chandra A; Loda M; Gillett C; Cathcart P; Challacombe B; Cook G; Cahill D; Santa Olalla A; Cahill F; George G; Rudman S; Van Hemelrijck M
BMC Cancer; 2017 Jul; 17(1):494. PubMed ID: 28732480
[TBL] [Abstract][Full Text] [Related]
25. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
26. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09).
Rothermundt C; Hayoz S; Templeton AJ; Winterhalder R; Strebel RT; Bärtschi D; Pollak M; Lui L; Endt K; Schiess R; Rüschoff JH; Cathomas R; Gillessen S
Eur Urol; 2014 Sep; 66(3):468-74. PubMed ID: 24412228
[TBL] [Abstract][Full Text] [Related]
27. Metformin - a Future Therapy for Neurodegenerative Diseases : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.
Markowicz-Piasecka M; Sikora J; Szydłowska A; Skupień A; Mikiciuk-Olasik E; Huttunen KM
Pharm Res; 2017 Dec; 34(12):2614-2627. PubMed ID: 28589443
[TBL] [Abstract][Full Text] [Related]
28. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Ben Sahra I; Laurent K; Loubat A; Giorgetti-Peraldi S; Colosetti P; Auberger P; Tanti JF; Le Marchand-Brustel Y; Bost F
Oncogene; 2008 Jun; 27(25):3576-86. PubMed ID: 18212742
[TBL] [Abstract][Full Text] [Related]
29. [Metformin, an antidiabetic molecule with anti-cancer properties].
Beck E; Scheen AJ
Rev Med Liege; 2013 Sep; 68(9):444-9. PubMed ID: 24180199
[TBL] [Abstract][Full Text] [Related]
30. Metabolic syndrome as a peculiar target for management of prostate cancer patients.
Conteduca V; Di Lorenzo G; Bozza G; Ardito R; Aieta M
Clin Genitourin Cancer; 2013 Sep; 11(3):211-20. PubMed ID: 23701880
[TBL] [Abstract][Full Text] [Related]
31. Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy.
Vona-Davis L; Rose DP
Curr Diabetes Rev; 2012 Mar; 8(2):116-30. PubMed ID: 22268396
[TBL] [Abstract][Full Text] [Related]
32. Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies.
Wang Y; Liu X; Yan P; Tang J; Chen T; Sun Y; Zhou W; Bi Y; Zhang ZJ
Eur J Cancer Prev; 2020 Jan; 29(1):42-52. PubMed ID: 30950925
[TBL] [Abstract][Full Text] [Related]
33. Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Christodoulou MI; Scorilas A
Curr Med Chem; 2017; 24(1):14-56. PubMed ID: 27604091
[TBL] [Abstract][Full Text] [Related]
34. Metformin--mode of action and clinical implications for diabetes and cancer.
Pernicova I; Korbonits M
Nat Rev Endocrinol; 2014 Mar; 10(3):143-56. PubMed ID: 24393785
[TBL] [Abstract][Full Text] [Related]
35. The pentacyclic triterpenoid, plectranthoic acid, a novel activator of AMPK induces apoptotic death in prostate cancer cells.
Akhtar N; Syed DN; Khan MI; Adhami VM; Mirza B; Mukhtar H
Oncotarget; 2016 Jan; 7(4):3819-31. PubMed ID: 26683363
[TBL] [Abstract][Full Text] [Related]
36. Anti-cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer.
Kheirandish M; Mahboobi H; Yazdanparast M; Kamal W; Kamal MA
Curr Drug Metab; 2018; 19(9):793-797. PubMed ID: 29663879
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy.
Karadeniz Z; Aynacıoğlu AŞ; Bilir A; Tuna MY
Med Hypotheses; 2020 Jan; 134():109420. PubMed ID: 31634770
[TBL] [Abstract][Full Text] [Related]
38. Does use of metformin protect against cancer in Type 2 diabetes mellitus?
Bo S; Benso A; Durazzo M; Ghigo E
J Endocrinol Invest; 2012 Feb; 35(2):231-5. PubMed ID: 22490993
[TBL] [Abstract][Full Text] [Related]
39. Metformin: from mechanisms of action to therapies.
Foretz M; Guigas B; Bertrand L; Pollak M; Viollet B
Cell Metab; 2014 Dec; 20(6):953-66. PubMed ID: 25456737
[TBL] [Abstract][Full Text] [Related]
40. Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis.
Deng D; Yang Y; Tang X; Skrip L; Qiu J; Wang Y; Zhang F
Diabetes Metab Res Rev; 2015 Sep; 31(6):595-602. PubMed ID: 25708557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
